In 2018, Nie et al. used two types of antibodies: a TNFR2-blocking and a CD25-targeted approach as a combination treatment in a colon cancer mouse model and breast cancer mouse model, resulting in the inhibition of cancer progression in both models [103]. Here, TNFRSF1B is linked to cancer.